OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

Oxford Cannabinoid Technologies Holdings Plc

Equities

OCTP

GB00BMVMRB86

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:18 2024-04-26 am EDT			5-day change	1st Jan Change
0.365 ^GBX	-1.35%		+8.96%	-41.60%

Apr. 11	Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment	AN
Apr. 09	Oxford Cannabinoid Technologies Holdings plc Appoints Timothy Henry Corn as A Director	CI

Oxford Cannabinoid shares up on applying to admit new shares

February 15, 2024 at 06:56 am EST

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Following the raising of GBP646,000 through the issue of 128.0 million new shares at a price of 0.5 pence each, as announced late last month, the company says it makes applications to the UK Financial Conduct Authority and London Stock Exchange to admit these shares to the Main Market in London. Expects the new shares to begin trading on Tuesday next week. Following admission, there will be 1.09 billion total Oxford Cannabinoid shares in issue.

Current stock price: 0.55 pence, up 7.8%

12-month change: down 31%

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
LONDON STOCK EXCHANGE PLC	8,934 GBX	+0.49%	-0.56%	59.47B
FTSE 100	8,140 PTS	+0.75%	+3.09%	-
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC	0.365 GBX	-1.35%	+8.96%	4.95M

Latest news about Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment	Apr. 11	AN
Oxford Cannabinoid Technologies Holdings plc Appoints Timothy Henry Corn as A Director	Apr. 08	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Lord Darren James Mott as Director	Apr. 07	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Lord Mott OBE as an Independent Non-Executive Director	Feb. 29	CI
Oxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024	Feb. 29	CI
Oxford Cannabinoid completes capital reorganisation	Feb. 16	AN
Oxford Cannabinoid Technologies Concludes Capital Reorganization	Feb. 16	MT
Oxford Cannabinoid Technologies Completes Equity Raise	Feb. 15	MT
Oxford Cannabinoid shares up on applying to admit new shares	Feb. 15	AN
Oxford Cannabinoid applies for new shares to be listed	Feb. 14	AN
Oxford Cannabinoid Technologies Applies for Admission of Redenominated Shares on London Bourse	Feb. 14	MT
Oxford Cannabinoid Technologies Enters Convertible Loan Note Agreements	Feb. 02	MT
Oxford Cannabinoid agrees GBP565,000 loan notes deal	Feb. 02	AN
Oxford Cannabinoid Technologies to Raise GBP1.2 Million via Subscriptions, Investment; Shares Plunge	Jan. 30	MT
Oxford Cannabinoid Technologies down after GBP1.2 million fundraise	Jan. 30	AN
Oxford Cannabinoid Technologies Holdings Plc Reports Earnings Results for the Half Year Ended October 31, 2023	Jan. 30	CI
Oxford Cannabinoid Technologies Files Patent for New Cannabinoid Compound in Europe	Jan. 10	MT
Oxford Cannabinoid stock goes high on Europe patent filing	Jan. 10	AN
Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2	Jan. 10	CI
Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive Director	Nov. 14	CI
Kingsley Capital reduces stake in Oxford Cannabinoid	23-10-20	AN
Oxford Cannabinoid Technologies Completes Dosing in Phase 1 Study for Lead Drug Candidate	23-10-10	MT
Oxford Cannabinoid completes Phase 1 study for lead asset OCT461201	23-10-10	AN
Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201	23-10-10	CI
Oxford Cannabinoid issues final dose of lead pharmaceutical asset	23-09-25	AN

Chart Oxford Cannabinoid Technologies Holdings Plc

Duration

Period

Chart Oxford Cannabinoid Technologies Holdings Plc

More charts

Company Profile

Oxford Cannabinoid Technologies Holdings plc is a United Kingdom-based pharmaceutical company developing prescription cannabinoid medicines. The Company is working with three types of cannabinoid compounds: synthesized phytocannabinoids, cannabinoid derivatives and novel chemical entities. Its drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and other therapeutic areas. It has a portfolio of four drug development programs: Program 1 (OCT461201), Program 2 (OCT130401), Program 3 (Cannabinoid derivative) and Program 4 (Cannabinoid derivative). Its OCT461201 is a new chemical entity, CB2 receptor agonist, chemically synthesized to behave like a cannabinoid. Its OCT130401 is a drug/device combination. It has a portfolio of over 500 derivatives and intellectual property rights, including 14 patent families and associated research data.

Sector

Biotechnology & Medical Research

Calendar

2024-10-08 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC	-41.60%	4.95M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Oxford Cannabinoid Technologies Holdings Plc

Equities

OCTP

GB00BMVMRB86

Biotechnology & Medical Research

Oxford Cannabinoid shares up on applying to admit new shares

Stocks mentioned in the article

Latest news about Oxford Cannabinoid Technologies Holdings Plc

Chart Oxford Cannabinoid Technologies Holdings Plc

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research